ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3120

RA Net: A Systems Biology Approach to Identify Genes Regulating Pathogenic Pathways in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)

Wei Wang1, RIchard Ainsworth2, Richard Stein2, Rizi Ai3 and Gary Firestein4, 1Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 2UC San Diego, La Jolla, CA, 3Chemistry and Biochemistry, UC San Diego, La Jolla, CA, 4Medicine, UCSD, La Jolla, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Epigenetics, fibroblasts and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 16, 2016

Title: Genetics, Genomics and Proteomics II

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) remains a significant unmet need despite improved therapy. Defining the interlaced nature of gene regulation and disease pathogenesis using integrative systems biology analysis is a powerful approach that can lead to experimentally verifiable predictions of novel therapeutic targets. We have developed a network that can potentially predict gene interactions that contribute to the pathogenic behavior of RA FLS and identify drug synergy to restore homeostasis.

Methods: Rheumatoid arthritis (RA) remains a significant unmet need despite improved therapy. Defining the interlaced nature of gene regulation and disease pathogenesis using integrative systems biology analysis is a powerful approach that can lead to experimentally verifiable predictions of novel therapeutic targets. We have developed a network that can potentially predict gene interactions that contribute to the pathogenic behavior of RA FLS and identify drug synergy to restore homeostasis. Methods: A novel computational systems biology method, known as RAnet, was designed and builds a probabilistic network model capturing the key regulations pertaining to the disease state of imprinted RA FLS. By comparing RA and osteoarthritis (OA) FLS, we curated genes that are critical in RA based on those that satisfied two of the three conditions: 1) differentially methylated genes (DMGs) in RA cells from 28 FLS lines, 2) differentially expressed genes (DEGs) in RA from 37 public microarray FLS lines, and 3) risk genes identified from GWAS studies. A set of 140 genes was selected to create a RA regulatory network. The network was determined by maximizing and adding or removing edges between randomly selected pairs of nodes. Using two and three gene combinations, predicted effects on gene expression were determined by calculating the Pearson and Spearman rank correlation coefficients.

Results: 403 gene-gene interactions were identified in RA Net. Because of the large number of potential combinations, we ranked and prioritized them in terms of the frequency in 1574 predicted models. The top gene/gene interactions included NFkB/GCLC, TP53/MDM2, CACL10/LINC0043, CYSLTR1/BHLHE22, and CARD16/C2orf88 because all were identified in at least 75% of the predicted models. We were also able to identify genes that regulate pathogenic pathways and cytokines in RA. For TNF regulation, top hits included TP53, PSMA4, IL1RN, CCR2, AIRE, JUN, and BMX. For IL-1 regulation, top hits included IL2RA, BMX, TNF, AIRE, and TP53. These core gene sets represent possible therapeutic targets that regulate these cytokines in RA. To determine combinations of genes that could be targeted to convert the RA FLS phenotype to a non-RA phenotype, we predicted the effect of knocking down combinations of genes. The maximum efficacy achievable with three-gene recipes (ravg = 0.576) is significantly improved compared with two-gene recipes (ravg = 0.517). The best three gene combination was the knockdown of genes the ring finger protein RNF144B (E3 ubiquitin-protein ligase), UGT2A3 and PLCH2. Interestingly, RNF144B expression is decreased by NSAIDs and RNF144B inhibitors are being developed as therapeutic agents.

Conclusion: This approach identifies synergistic therapeutic targets in RA using systems biology. The genes that regulate pathogenic pathways repeatedly appear in top gene “recipes” and could be promising candidates for combination therapy. This novel in silico method could offer a new way to determine disease mechanisms in RA.


Disclosure: W. Wang, None; R. Ainsworth, None; R. Stein, None; R. Ai, None; G. Firestein, Janssen Pharmaceutica Product, L.P., 2.

To cite this abstract in AMA style:

Wang W, Ainsworth R, Stein R, Ai R, Firestein G. RA Net: A Systems Biology Approach to Identify Genes Regulating Pathogenic Pathways in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/ra-net-a-systems-biology-approach-to-identify-genes-regulating-pathogenic-pathways-in-rheumatoid-arthritis-ra-fibroblast-like-synoviocytes-fls/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ra-net-a-systems-biology-approach-to-identify-genes-regulating-pathogenic-pathways-in-rheumatoid-arthritis-ra-fibroblast-like-synoviocytes-fls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology